Tous les comptes rendus municipaux disponibles sur Pappers Politique !

Pappers Politique vous permet d'accéder et d'explorer les comptes rendus, délibérations et procès verbaux de conseils municipaux :
  • Anticipez les besoins et projets dans les municipalités et plus particulièrement les appels d'offre à venir.
  • Identifiez les communes actives sur vos thématiques de prédilection
Réserver une démo avec un expert

COVID-19 vaccinations

Question écrite de M. Georg MAYER - Commission européenne

Question de M. Georg MAYER, M. Harald VILIMSKY,

Diffusée le 20 mars 2024

Subject: COVID-19 vaccinations

For many months there have been calls for full disclosure of how COVID-19 vaccines were procured, particularly by disclosing chats and contracts between Commission President Ursula von der Leyen and the vaccine manufacturer Pfizer. They have been completely ignored and now another tender procedure has been launched to purchase almost 150 million doses of new mRNA COVID vaccines. Just a few months ago, however, millions of doses of COVID-19 vaccines were thrown away because they had expired and demand for them had plummeted. A Pfizer spokesperson has also announced that all messages between the EU institutions and the company concerning the ongoing tender will be confidential.

1. Why is the Commission once more ordering such large quantities directly?

2. Will the contracts between the Commission and the company winning the tender be published this time, and if not, why not?

3. Why does the Commission see no need to disclose details of such high expenditure to EU citizens in a transparent and comprehensible manner?

Submitted:21.3.2024

Réponse - Commission européenne

Diffusée le 30 juin 2024

Answer given by Ms Kyriakides on behalf of the European Commission (1 July 2024)

As the Commission pointed out in its reply to Written Question P-356/24, the countries participating in the ongoing tender procedure HERA/2023/CPN/0011 (in accordance with the Joint Procurement Agreement adopted on 10 April 2014 implementing Article 12 of Regulation (EU) 2022/2371 (1) on serious cross-border threats to health) have expressed the need to have access to a COVID-19 mRNA vaccine to ensure preparedness and adaptation for the continued evolution of COVID-19 variants, which, in combination with other respiratory viruses, remains a health threat.

In view thereof, as requested by the Member States and other participating countries, the Commission has launched a joint procurement procedure together with and for the participating countries.

The framework contract that would result from this competitive procedure would be flexible, meaning that countries would only order vaccine doses upon need.

The maximum ceiling of vaccines doses that can be ordered under the framework contract has been established based on the estimated yearly needs of the participating countries in case of crisis.

The Commission is committed to high standards of transparency and openness regarding the joint procurement procedures, in line with the applicable legal framework.

On this basis, the Commission has already published all the contracts for the procurement of COVID-19 vaccine s (2), while safeguarding the right to protect certain commercially confidential information.

On the same basis, once a new contract is signed, the Commission will inter alia take into account the principle of transparency, the protection of legitimate commercial interests and the applicable contractual terms to take a decision on public disclosure.

1 ∙ ⸱ https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32022R2371

2 ∙ ⸱ https://commission.europa.eu/strategy-and-policy/coronavirus-response/public-health/eu-vaccines-strategy_en#documents



Questions similaires

Déposée le 9 février 2021 à 23h00
Similarité de la question: 61% Similarité de la réponse: 65%
Déposée le 26 mai 2021 à 22h00
Similarité de la question: 68% Similarité de la réponse: 74%
Déposée le 23 novembre 2020 à 23h00
Similarité de la question: 63% Similarité de la réponse: 72%
Déposée le 2 décembre 2020 à 23h00
Similarité de la question: 65% Similarité de la réponse: 72%
Déposée le 20 mai 2021 à 22h00
Similarité de la question: 63% Similarité de la réponse: 74%
Déposée le 1 février 2021 à 23h00
Similarité de la question: 68% Similarité de la réponse: 69%